China’s Ministry of Commerce announced it will lift the import restrictions on Illumina DNA sequencers effective Nov. 10, reversing a ban imposed earlier this year. The move restores a key commercial channel for Illumina and may ease supply constraints for Chinese clinical and research labs that had been forced to adopt domestic or alternative platforms. The decision follows bilateral trade talks and has implications for global sequencing competition, regulatory compliance, and adoption rates for long‑read and short‑read platforms in China’s large diagnostics and genomics market. Who: Illumina, Chinese Ministry of Commerce, Chinese clinical labs; why it matters: reopening China restores a major addressable market for sequencing vendors and could accelerate clinical genomics expansion.